Actions of Probiotics on Trinitrobenzenesulfonic Acid-Induced Colitis in Rats

Takahiko Shiina, Takeshi Shima, Kiyotada Naitou, Hiroyuki Nakamori, Yuuki Sano, Kazuhiro Horii, Masaki Shimakawa, Hiroshi Ohno, and Yasutake Shimizu

1Department of Basic Veterinary Science, Laboratory of Physiology, The United Graduate School of Veterinary Sciences, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan
2Biofermin Kobe Research Institute, Biofermin Pharmaceutical Co. Ltd., 7-3-4 Ibukidai-Higashimachi, Nishi-ku, Kobe 651-2242, Japan

Correspondence should be addressed to Takahiko Shiina; tshiina@gifu-u.ac.jp

Received 23 July 2015; Revised 25 September 2015; Accepted 27 September 2015

We investigated the actions of probiotics, *Streptococcus faecalis* 129 BIO 3B (SF3B), in a trinitrobenzenesulfonic acid- (TNBS-) induced colitis model in rats. After TNBS was administered into the colons of rats for induction of colitis, the rats were divided into two groups: one group was given a control diet and the other group was given a diet containing SF3B for 14 days. There were no apparent differences in body weight, diarrhea period, macroscopic colitis score, and colonic weight/length ratio between the control group and SF3B group, suggesting that induction of colitis was not prevented by SF3B. Next, we investigated whether SF3B-containing diet intake affects the restoration of enteric neurotransmissions being damaged during induction of colitis by TNBS using isolated colonic preparations. Recovery of the nitricergic component was greater in the SF3B group than in the control group. A compensatory appearance of nontachykininergic and noncholinergic excitatory components was less in the SF3B group than in the control group. In conclusion, the present study suggests that SF3B-containing diet intake can partially prevent disruptions of enteric neurotransmissions induced after onset of TNBS-induced colitis, suggesting that SF3B has therapeutic potential.

1. Introduction

Inflammatory bowel disease (IBD) is a group of chronic, incurable inflammatory disorders of the gastrointestinal tract, including Crohn’s disease and ulcerative colitis [1, 2]. IBD has become almost a global disease affecting people of almost all ages including the pediatric population [3, 4]. A convenient approach to study the pathogenesis of human IBD is to use animal models of IBD [4, 5]. Various animal models have been established to study IBD including chemical-induced colitis models such as trinitrobenzenesulfonic acid (TNBS), dextran sodium sulphate (DSS), and oxazolone-induced colitis models [1, 4].

Intracolonic application of TNBS induces colonic inflammation characterized by increased leukocyte infiltration, edema, and ulceration [4]. In addition, TNBS-induced colitis leads to alterations in enteric neuronal transmission regulating gastrointestinal motility, which is commonly found in IBD [6–10]. For instance, we previously demonstrated by using a TNBS-induced colitis model that the colonic inflammation causes indiscriminate damage to enteric neurons and that noncholinergic nontachykininergic excitatory neural components appear during restoration of inflammation probably as a result of a compensatory neurogenesis [11]. TNBS-induced colitis model animals have been widely used for identifying anti-inflammatory components such as plant extracts [12], seed oils [13], and probiotics [2, 14].

Probiotics are organisms that provide a desired and beneficial effect on human health. The probiotic *Streptococcus faecalis* 129 BIO 3B (SF3B: strain currently classified as *Enterococcus faecium*), which is a normal bowel commensal and lactic acid bacterium, has been reported to have various actions such as intestinal regulation [15, 16]. SF3B attenuated abdominal pain in an experimental rat model of TNBS-induced visceral hypersensitivity [16], suggesting that SF3B might affect the pathogenesis of TNBS-induced dysfunctions.
including colitis. In addition, growing evidence for a role of intestinal microflora in the development of IBD has led to studies on the therapeutic potential of modifying the composition of intestinal microbiota using probiotics [14]. In accordance with this, Yoshimatsu et al. recently reported that probiotics might be effective for maintaining clinical remission in patients with quiescent ulcerative colitis [17]. Hence, in the present study, we studied actions of probiotics on TNBS-induced colitis with focus on the alteration/recovery in the composition of intestinal microbiota using probiotics [14]. In accordance with this, Yoshimatsu et al. recently reported that probiotics might be effective for maintaining clinical remission in patients with quiescent ulcerative colitis [17]. Hence, in the present study, we studied actions of probiotics on TNBS-induced colitis with focus on the alteration/recovery in the composition of intestinal microbiota using probiotics [14].

2. Materials and Methods

2.1. Animals. Male Wistar rats (8–11 weeks of age, 200–300 g in weight) were obtained from Japan SLC (Shizuoka, Japan). They were maintained in plastic cages at a temperature of 30°C in weight) were obtained from Japan SLC (Shizuoka, Japan). They were maintained in plastic cages at 30°C.

2.2. Preparation of Bacterial Powder and Bacterial Powder-Containing Diet. Dry powder consisting of SF3B (5 × 10^{11} cfu/g) isolated from human feces and a vehicle composed mainly of dextrin were used. This powder was supplied by Biofermin Pharmaceutical Co. Ltd. (Kobe, Japan). The compositions of diets used in this experiment are shown in Table 1.

2.3. Induction of Colitis and Feeding Program. After overnight fasting, animals were anesthetized with isoflurane. Then, they were given 1 mg of TNBS dissolved in 0.8 mL of 40% ethanol (v/v) by means of a silicon catheter inserted 7 cm through the anus. The animals were maintained in a head-down position for about 1 min to prevent leakage of the intracolonic solution. Animals were divided into two groups: one group was given a control diet (CONT group) and the other group was given a diet containing SF3B (SF3B group). The animals were maintained in their plastic cages and used at 7 days or 14 days after receiving TNBS. Macroscopic colitis score was calculated according to the criteria shown in Table 2.

2.4. Tissue Preparation. Animals were anesthetized by isoflurane and exsanguinated via the carotid artery. The abdominal cavity was opened immediately, and a 3-4 cm long segment of the distal colon (2 cm from the anus) was dissected out and immersed in modified Tyrode’s solution (see below) at room temperature. The intraluminal contents were flushed using a small cannula filled with modified Tyrode’s solution.

2.5. Mechanical Recordings. A segment of the distal colon of 3-4 cm length was mounted in a Magnus tube (20 mL in capacity) filled with modified Tyrode’s solution (pH 7.4). The solution was continuously bubbled with 95% O_{2} + 5% CO_{2} gas mixture and maintained at 37°C. The distal end of each segment was tied to organ holders and the proximal end was secured with a silk thread to an isometric force transducer. The preparation was stimulated electrically by means of two platinum electrodes, one of which was placed in the lumen of the preparation and the other in the bathing solution (coaxial stimulation). Supramaximal rectangular pulses of 80 V in intensity and 0.5 msec in duration were delivered by using an electrical stimulator (model SEN-3301, Nihon Kohden, Tokyo, Japan) with frequency spectra of 20 Hz for 1 sec. Longitudinal contractile activity was recorded isometrically with a force transducer (T7-8-240, Orientec, Tokyo, Japan). An initial tension of 1.0 g was applied to the colonic preparations, which were subsequently allowed to equilibrate for 30 min. At the end of this period, the tension created by the segment was considered as the resting tension and no further mechanical adjustment was made during experimentation. Isometric responses were filtered and amplified by an amplifier (NEC, ASI202, Tokyo, Japan) and recorded using a PowerLab system (AD Instruments, Bella Vista, NSW, Australia).

2.6. Solutions and Drugs. During experiments for recording mechanical responses, tissues were maintained in modified Tyrode’s solution consisting of (in mM) NaCl 136.9, KCl 2.68, CaCl_{2} 1.80, MgCl_{2} 1.0, NaH_{2}PO_{4} 0.41, NaHCO_{3} 11.90, and glucose 5.55. Tetrodotoxin was used as a blocker of voltage-dependent sodium channels on neurons. Atropine was used to block muscarinic acetylcholine receptors on smooth muscle cells. N-Acetyl-L-tryptophan 3,5-bis (trifluoromethyl) benzyl ester (L-732,138) and (S)-N-methyl-N[4-(4-acetylamino-4-phenylpiperidino)-2-(3,4-dichlorophenyl) butyl] benzamide (SR48968) were used to block tachykinin NK_{1} and tachykinin NK_{2} receptors, respectively. Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME) was used as a nitric oxide (NO) synthase (NOS) inhibitor. L-732,138 and L-NAME were obtained from Sigma (St. Louis, MO, USA). Atropine sulfate salt monohydrate, TNBS, and tetrodotoxin were obtained from Wako (Osaka, Japan). SR48968 was a gift from Sanofi-Synthelabo (Montpellier, France). L-732,138

| Feature graded | Grade | Description |
|----------------|-------|-------------|
| Feces          | 0     | Normal      |
|                | 1     | Loose       |
| Mucosa damage  | 0     | None        |
|                | 1     | Mild        |
|                | 2     | Moderate    |
|                | 3     | Severe      |
| Adhesion       | 0     | None        |
|                | 1     | Mild        |
|                | 2     | Severe      |

Table 1: Compositions of experimental diets (%).

|                | Control diet | SF3B diet |
|----------------|--------------|-----------|
| CE-2*          | 90           | 90        |
| SF3B powder    | —            | 10        |
| Dextrin        | 10           | —         |

*CE-2: standard diet (CLEA Japan, Tokyo, Japan).

Table 2: Criteria for scoring of colitis by macroscopic assessment.
and SR48968 were dissolved in ethyl acetate and ethanol, respectively. The vehicles (ethanol and ethyl acetate) for the drugs alone had no effect on basal tone. Other drugs were dissolved in distilled water. The drug concentrations given in the test were final concentrations in the bath solution.

2.7. RNA Isolation and Reverse Transcription-Polymerase Chain Reaction (RT-PCR). The expression of mRNA was assessed by RT-PCR. Total cellular RNA was extracted from tissue homogenates of the rat colon using TRIzol reagent (Thermo Fisher Scientific Inc., Waltham, MA, USA). First-strand cDNA was synthesized from 2 μg of total RNA by using SuperScript III Reverse Transcriptase (Fisher Scientific Inc.) and Random Primers (Fisher Scientific Inc.). The absence of PCR-amplified DNA fragments in the samples without reverse transcription indicated the isolation of RNA free from genomic DNA contamination. The PCR was performed with platinum Taq DNA polymerase (Fisher Scientific Inc.). The primer sets were as follows: inducible NOS (iNOS) sense 5′-TAG AAA CAA CAG GAA CCT AC-3′ and antisense 5′-AAC ATC TCC TGG TGG AAC A-3′ (predicted size = 925 bp); neuronal NOS (nNOS) sense 5′-CCG GAA TTC CAT CCT GAT CCA TGG AA-3′ and antisense 5′-CCG AAT TCC TCC AGG GTG TCC ACC GCA TG-3′ (predicted size = 617 bp); c-Myc sense 5′-AAG AGA AGT TCT ATT TCT ATC ACC AG-3′ and antisense 5′-TTG ATGGGG GGA CTG CTC CTC CTT CAT CCC AG-3′ (predicted size = 771 bp); CyclinD1 sense 5′-AGG AGC AGA AGT CGG CCC ACC TTC ATG CCT TC-3′ and antisense 5′-TTG CTGTGGAATCCT CGA TCA GCC ATT GAC ACA-3′ (predicted size = 387 bp); and 5′-TCA GGA TCT CTC TTC TCT CAT AA-3′ (predicted size = 880 bp); and β-actin sense 5′-GGA AGC CGC CAA AAA CCT TG-3′ and antisense 5′-GGA AGC AGA AGT GCG AAG AG-3′ (predicted size = 642 bp); housekeeping genes with the following primers: GAPDH sense 5′-GCC GGG CTG CCC-3′ and antisense 5′-TGA ACT GAG TGA GAA CCT AC-3′ (predicted size = 224 bp); β-actin sense 5′-ACC ACC ATC GCC ATC CCC AG-3′ and antisense 5′-TCA GGA TCT CTC TTC TCT CAT AA-3′ (predicted size = 387 bp).

2.8. Macroscopic Assessment of Colitis. The isolated colon segments were examined visually, and their damage was scored. Macroscopic colitis scores were assigned values of 0–6 as shown in Table 2. In addition, colonic weight/length ratio was calculated as a parameter for evaluating inflammation damage, since colonic inflammation can result in an increase in weight of the colon and decrease in length of the colon [18].

2.9. Data Analysis. Data are presented as means ± standard deviation (S.D.). n indicates the number of experiments performed using different tissue preparations from different animals. The significance of differences between mean values was determined by one-way or two-way analysis of variance followed by the Turkey-Kramer test for comparison of multiple groups or by Student's t-test or Mann-Whitney U test for comparison of two groups. A P value less than 0.05 denotes the presence of a statistically significant difference.

3. Results

3.1. Effects of SF3B-Containing Diet Intake on TNBS-Induced Colitis in Rats. TNBS was injected into the distal colon of each rat to induce colitis, and then a control diet or a diet containing SF3B was given for 14 days. Body weights in both the CONT group and SF3B group decreased within the initial 3 days after treatment with TNBS but recovered gradually as days passed (Figure 1). There was no significant difference in body weight changes between the groups. In contrast, the weight of intact animals increased during the same period. Diarrhea occurred 1–3 days after TNBS treatment and persisted for about 10–12 days in both groups (Figure 2(a)). Macroscopic observation showed that treatment with TNBS induced visible inflammation in the colon, as indicated by the macroscopic colitis score (Table 2): close to 0 in intact rats versus about 2-3 in the CONT group and SF3B group at 14 days after TNBS treatment (Figure 2(b)). Colonic weight/length ratios in the CONT group and SF3B group at 14 days after TNBS treatment were higher than the ratio in the intact group, while there was no significant difference between the CONT group and SF3B group (Figure 2(c)).
3.2. Effects of SF3B-Containing Diet Intake on Inflammation-Induced Changes in Nitric Responses in Colonic Motor Functions. At 14 days after TNBS treatment, we investigated functions of enteric neurons in motility of the inflamed colon using an in vitro system. In segments of the distal colon from the intact group, spontaneous contractions were observed (Figure 3(a)). Application of EFS induced contractile responses in the rat colon (Figure 3(a)). The EFS-induced contractile response was abolished by application of tetrodotoxin (1 μM), a blocker of voltage-dependent sodium channels on neurons (data not shown). To determine whether NO influences mechanical responses in the rat colon, L-NAME (200 μM), a NOS inhibitor, was applied. In all of the preparations from the intact group (n = 7), as shown in Figure 3(a), L-NAME application increased the frequency and amplitude of spontaneous contractions, suggesting that the colonic contractile activity is subject to tonic nitrergic inhibitory control. In agreement with this, amplitude of the EFS-induced contraction was increased after application of L-NAME (Figure 3(a)). In contrast, 36.4% of the preparations from the CONT group (n = 11) were resistant to L-NAME: spontaneous contractions and EFS-induced contractions were not enhanced even in the presence of L-NAME (200 μM), a blocker of NO synthase (data not shown). In contrast, in half of the preparations from the SF3B group (n = 9), combined application of tachykininergic and cholinergic antagonists almost totally abolished EFS-induced contraction in a manner similar to that in the intact group (Figure 3(c)).

3.3. Effects of SF3B-Containing Diet Intake on Inflammation-Induced Changes in Excitatory Responses in Colonic Motor Functions. Next, we examined the effect of SF3B-containing diet on neuronal components regulating EFS-induced contractile responses in the inflamed colon at 14 days after TNBS treatment. To simplify the interpretation of results of pharmacological experiments, blockers were applied under the condition in which the inhibitory components were eliminated by L-NAME (200 μM). In preparations of the intact group (n = 7), as shown in Figure 4(a), combined application of blockers for tachykinin NK₁ receptors and tachykinin NK₂ receptors (L-732,132 and SR48968, 2 μM, resp.) significantly diminished the EFS-evoked contractile responses (Figure 4(a)). The contraction being resistant to tachykininergic antagonists was blocked by the cumulative application of atropine (5 μM), a blocker for muscarinic cholinoceptors (Figure 4(a)). In contrast, in the majority of preparations from the CONT group (n = 11), EFS-induced contractile response was not completely blocked by combined application of tachykininergic and cholinergic antagonists (Figure 4(b)). The noncholinergic/nontachykininergic response was abolished by tetrodotoxin (1 μM), an inhibitor of neurogenic responses (data not shown). In contrast, in half of the preparations from the SF3B group (n = 9), combined application of tachykininergic and cholinergic antagonists almost totally abolished EFS-induced contraction in a manner similar to that in the intact group (Figure 4(c)).

3.4. Effects of SF3B-Containing Diet Intake on Expression of mRNAs of Inflammation-Related and Tissue Regeneration-Related Genes and an Enteric Neuron-Expressing Gene in the Inflamed Colon. Expression of iNOS, Atoh1, CyclinD1, c-Myc, Lgr5, Hes-1, Notch1, and nNOS genes in the inflamed colon was analyzed by RT-PCR. After treatment with TNBS, the expression of iNOS mRNA was increased, while the expressions of other inflammation-related and tissue regeneration-related gene mRNAs were decreased (Figures 5(a), 5(b), and 5(c)). Expression levels of iNOS and CyclinD1 mRNAs in the SF3B group were lower than those in the CONT group at 7 days after treatment with TNBS (Figures 5(a) and 5(b)). On the other hand, expression level of Atoh1 mRNA in the SF3B group was higher than that in the CONT group at 7 days after TNBS application (Figure 5(c)). In addition, expression level of nNOS mRNA in the SF3B group
Figure 3: Effects of a NOS inhibitor on spontaneous contractions and electrical field stimulation- (EFS-) induced contractions in isolated colonic preparations from rats. Representative tracings of mechanical responses in the absence and presence of a NOS inhibitor, L-NAME (200 μM), in an intact rat (a), a TNBS-treated rat with the control diet at 14 days after TNBS treatment (b), and a TNBS-treated rat with the SF3B-containing diet at 14 days after TNBS treatment (c) are shown. Circles indicate the points of EFS.

at 14 days after treatment with TNBS was higher than that in the SF3B group at 7 days after TNBS application (Figure 5(d)). There was no significant difference in expression levels of other genes between the SF3B group and CONT group.

4. Discussion

In the present study, we tried to determine whether SF3B has beneficial actions on IBD, especially the recovery phase of IBD, by using a TNBS-induced colitis model in rats. We found no apparent differences in body weight, diarrhea period, macroscopic colitis score, and colonic weight/length ratio between the control diet group and SF3B-containing diet group. On the basis of these results, induction and progression of colitis itself did not seem to be prevented even by taking SF3B-containing diet at least in this experimental condition. However, a remarkable finding of our study is that enteric neural components, which are impaired by an acute inflammatory process, are normally restored by ingestion of an SF3B-containing diet. Considering that alterations in enteric neural components being promoted following transient intestinal inflammation, as manifested in the CONT group in this study, can be a cause of abnormal intestinal motility [11, 19–21], the action of SF3B to bring about normal restoration would be beneficial for treatment of IBD.

Disruption of enteric neurotransmissions is one of the principle causes of colitis-induced abnormal intestinal motility [7–11, 22, 23]. In the present study, we investigated whether ingestion of an SF3B-containing diet affects restoration of
Figure 5: Effects of SF3B-containing diet intake on expression of mRNAs of inflammation-related and tissue regeneration-related genes in the inflamed colon. Expression levels of iNOS (a), CyclinD1 (b), Atoh1 (c), and nNOS (d) genes in colons of the CONT group (n = 5) and SF3B group (n = 5) at 7 or 14 days after TNBS treatment and of the intact group (n = 3) were analyzed by RT-PCR. Summary graphs showing relative values of mRNA expression calculated by taking the value of the respective β-actin mRNA as unity (1.0). Each bar represents the mean ± S.D. *P < 0.05 and **P < 0.01, comparison between the CONT group and SF3B group at the same day after TNBS treatment or between the SF3B groups at different day after TNBS treatment.

nitrergic, tachykinergic, and cholinergic neurotransmissions being damaged during induction of colitis by TNBS. Recovery of the nitrergic component as assessed by increases in frequency and amplitude of spontaneous contractions after application of L-NAME was greater in the SF3B group than in the CONT group. This suggests that ingestion of SF3B accelerates restoration of the nitrergic component. In accordance with this, the expression level of nNOS gene at 14 days after treatment with TNBS was higher than that at 7 days after treatment with TNBS in the SF3B group but not in the CONT group. Since the inhibitory nitrergic component of the enteric nervous system plays an important role in the regulation of intestinal motility, the effect of SF3B would be accessible to avoid persistent alteration of motility patterns commonly observed after the resolution of intestinal inflammation [19, 21]. In addition, appearance of nontachykinergic and noncholinergic excitatory components was less in the SF3B group than in the CONT group. The appearance of unusual neural components can be considered to be a compensatory mechanism to maintain intestinal motility [11]. However, excessive compensation might not always be beneficial for normal functions. Thus, less expression of the nontachykinergic and noncholinergic excitatory components can be appreciated as a valuable action of SF3B.

IBD is an important etiologic factor in the development of colorectal cancer [24]. It has been pointed out that several molecular alterations associated with IBD are related to colorectal cancer. For instance, activation of CyclinD1-mediated cell proliferation and high activity of iNOS might contribute to colon oncogenesis [20, 25]. Interestingly, SF3B-containing diet intake reduced the expression of iNOS and
CyclinD1 mRNA compared to that in rats fed the control diet. It is therefore expected that the risk for IBD-associated colorectal cancer would be alleviated by the action of SF3B.

Although probiotics have been reported to exert various actions in humans and animals, the mechanisms of their actions are not completely understood [14]. Probiotics can occupy the physical space and interact with intestinal tissue or release bioactive products/metabolites, resulting in the blocking of pathogenic bacteria, enhancement of barrier function, and alteration of the mucosal immune system [14]. In fact, it had been reported that ingestion of Streptococcus faecalis resulted in increasing bifidobacteria and enterococci of the intestinal flora in rats [26]. Moreover, probiotics can exert anti-inflammatory action by reducing the production of proinflammatory cytokines [14]. In accordance with this, SF3B-containing diet intake inhibited expression of a proinflammation marker gene iNOS. Considering that enteric neuroplasticity evoked by inflammation such as that in IBD might be caused by proinflammatory cytokines from activated immune cells [6, 7, 14], SF3B might prevent colitis-associated disruptions of enteric neurons by blocking activation of the inflammatory response at least partially.

In conclusion, the present study suggests that ingestion of an SF3B-containing diet can partially prevent disruptions of enteric neurotransmissions induced after onset of TNBS-induced colitis and inhibit the expression of genes involved in oncogenesis, suggesting that SF3B has therapeutic potential.

**Disclosure**

This study was a part of studies on actions of Streptococcus faecalis 129 BIO 3B. Biofermin Pharmaceutical Co. Ltd. had no role in the study design, conduct of the study, data collection, data interpretation, or preparation of the report.

**Conflict of Interests**

M. Shimakawa and H. Ohno are employees of Biofermin Pharmaceutical Co. Ltd. (Kobe, Japan).

**Acknowledgments**

The authors are indebted to Ms. Ayako Takahashi and Noriko Endo (Gifu University, Japan) for their technical support. This study was partially funded by Biofermin Pharmaceutical Co. Ltd.

**References**

[1] D. Corridoni, K. O. Arseneau, and F. Cominelli, “Inflammatory bowel disease,” *Immunology Letters*, vol. 161, no. 2, pp. 231–235, 2014.

[2] S. Guandalini, “Are probiotics or prebiotics useful in pediatric irritable bowel syndrome or inflammatory bowel disease?” *Frontiers of Medicine*, vol. 1, article 23, 2014.

[3] N. A. Molodecky, L. S. Soon, D. M. Rabi et al., “Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review,” *Gastroenterology*, vol. 142, no. 1, pp. 46.e42–54.e42, 2012.

[4] P. K. Randhawa, K. Singh, N. Singh, and A. S. Jaggi, “A review on chemical-induced inflammatory bowel disease models in rodents,” *Korean Journal of Physiology and Pharmacology*, vol. 18, no. 4, pp. 279–288, 2014.

[5] N. Goyal, A. Rana, A. Ahlawat, K. R. V. Bijjem, and P. Kumar, “Animal models of inflammatory bowel disease: a review,” *Inflammopharmacology*, vol. 22, no. 4, pp. 219–233, 2014.

[6] C. Giaroni, F. De Ponti, M. Cosentino, S. Lecchini, and G. Frigo, “Plasticity in the enteric nervous system,” *Gastroenterology*, vol. 117, no. 6, pp. 1438–1458, 1999.

[7] A. E. Lomax, E. Fernández, and K. A. Sharkey, “Plasticity of the enteric nervous system during intestinal inflammation,” *Neurogastroenterology and Motility*, vol. 17, no. 1, pp. 4–15, 2005.

[8] G. M. Mawe, S. M. Collins, and T. Shea-Donohue, “Changes in enteric neural circuitry and smooth muscle in the inflamed and infected gut,” *Neurogastroenterology and Motility*, vol. 16, no. 1, pp. 133–136, 2004.

[9] D. M. Moynes, G. H. Lucas, M. J. Beyak, and A. E. Lomax, “Effects of inflammation on the innervation of the colon,” *Toxicologic Pathology*, vol. 42, no. 1, pp. 111–117, 2014.

[10] V. Vasina, G. Barbara, L. Talamonti et al., “Enteric neuroplasticity evoked by inflammation,” *Autonomic Neuroscience: Basic & Clinical*, vol. 126-127, pp. 264–272, 2006.

[11] T. Shina, Y. B. Gurung, Y. Suzuki, T. Takewaki, and Y. Shimizu, “Alteration of neuromuscular transmissions in the hamster colon following the resolution of TNBS-induced colitis,” *Journal of Physiological Sciences*, vol. 63, no. 4, pp. 241–249, 2013.

[12] X. Liu and J. Wang, “Anti-inflammatory effects of iridoid glycosides fraction of Foliun syringae leaves on TNBS-induced colitis in rats,” *Journal of Ethnopharmacology*, vol. 133, no. 2, pp. 780–787, 2011.

[13] F. Isik, T. Tunali Akbay, A. Yarat et al., “Protective effects of black cumin (Nigella sativa) oil on TNBS-induced experimental colitis in rats,” *Digestive Diseases and Sciences*, vol. 56, no. 3, pp. 721–730, 2011.

[14] G. R. Veerappan, J. Betteridge, and P. E. Young, “Probiotics for the treatment of inflammatory bowel disease,” *Current Gastroenterology Reports*, vol. 14, no. 4, pp. 324–333, 2012.

[15] M. Kumada, M. Motegi, R. Nakao et al., “Inhibiting effects of Enterococcus faecium non-biofilm strain on Streptococcus mutans biofilm formation,” *Journal of Microbiology, Immunology and Infection*, vol. 42, no. 3, pp. 188–196, 2009.

[16] M. Shimakawa, S. Tsumine, Y. Makizaki, T. Komada, H. Ohno, and H. Yamamura, “Effects of Streptococcus facalis 129 BIO 3B on abdominal pain in a rat model,” *Journal of Pharmacological Sciences*, vol. 121, supplement 1, p. 114, 2013.

[17] Y. Yoshimatsu, A. Yamada, R. Furukawa et al., “Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis,” *World Journal of Gastroenterology*, vol. 21, no. 19, pp. 5985–5994, 2015.

[18] X. Lei, M. Liu, Z. Yang, M. Ji, X. Guo, and W. Dong, “Thymoquinone prevents and ameliorates dextran sulfate sodium-induced colitis in mice,” *Digestive Diseases and Sciences*, vol. 57, no. 9, pp. 2296–2303, 2012.

[19] G. Barbara, B. A. Vallance, and S. M. Collins, “Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice,” *Gastroenterology*, vol. 113, no. 4, pp. 1224–1232, 1997.

[20] Y. B. Gurung, Y. Shimizu, T. Shina, M. E. Mahmoud, S. Saito, and T. Takewaki, “Impairment and restoration of spontaneous contractile activity of longitudinal smooth muscles in the TNBS-infamed hamster distal colon,” *Biomedical Research*, vol. 28, no. 6, pp. 301–308, 2007.
[21] A. E. Lomax, J. R. O’Hara, N. P. Hyland, G. M. Mawe, and K. A. Sharkey, “Persistent alterations to enteric neural signaling in the guinea pig colon following the resolution of colitis,” *American Journal of Physiology: Gastrointestinal and Liver Physiology*, vol. 292, no. 2, pp. G482–G491, 2007.

[22] K. J. Gross and C. Pothoulakis, “Role of neuropeptides in inflammatory bowel disease,” *Inflammatory Bowel Diseases*, vol. 13, no. 7, pp. 918–932, 2007.

[23] T.-S. Sung, J.-H. La, T.-W. Kim, and I.-S. Yang, “Alteration of nitrergic neuromuscular transmission as a result of acute experimental colitis in rat,” *Journal of Veterinary Science*, vol. 7, no. 2, pp. 143–150, 2006.

[24] M. Yashiro, “Molecular alterations of colorectal cancer with inflammatory bowel disease,” *Digestive Diseases and Sciences*, vol. 60, no. 8, pp. 2251–2263, 2015.

[25] N. Gopalakrishnan, M. Saravanakumar, P. Madankumar, M. Thiyagu, and H. Devaraj, “Colocalization of β-catenin with Notch intracellular domain in colon cancer: a possible role of Notch1 signaling in activation of CyclinD1-mediated cell proliferation,” *Molecular and Cellular Biochemistry*, vol. 396, no. 1-2, pp. 281–293, 2014.

[26] S. Katsumata, “Effects of oral administration of lactic acid bacteria preparation on enterobacterial flora in rats,” *Journal of the Japan Pediatric Society*, vol. 58, no. 10, pp. 893–899, 1954 (Japanese).